315 related articles for article (PubMed ID: 28449473)
21. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of PD-L1-negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis.
Chai Y; Wu X; Zou Y; Zhang X; Bai H; Dong M; Duan J
Thorac Cancer; 2022 Nov; 13(22):3124-3132. PubMed ID: 36168110
[TBL] [Abstract][Full Text] [Related]
23. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Xu Y; Wan B; Chen X; Zhan P; Zhao Y; Zhang T; Liu H; Afzal MZ; Dermime S; Hochwald SN; Hofman P; Borghaei H; Lin D; Lv T; Song Y;
Transl Lung Cancer Res; 2019 Aug; 8(4):413-428. PubMed ID: 31555516
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
25. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
[TBL] [Abstract][Full Text] [Related]
27. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Huang J; Zhang Y; Sheng J; Zhang H; Fang W; Zhan J; Zhou T; Chen Y; Liu L; Zhang L
Onco Targets Ther; 2016; 9():5867-5874. PubMed ID: 27713640
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
Duan X; Du H; Qi R; Yuan M; Shi J
Exp Ther Med; 2023 May; 25(5):216. PubMed ID: 37123204
[TBL] [Abstract][Full Text] [Related]
30. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
[No Abstract] [Full Text] [Related]
32. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
Deng S; Yang Q; Shu X; Lang J; Lu S
Front Pharmacol; 2019; 10():1063. PubMed ID: 31607917
[No Abstract] [Full Text] [Related]
33. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer.
Lin L; Xiao L; Li L; Chen C; Zhang H; Yu C; Zhang L; Wei A; Li W
Front Pharmacol; 2024; 15():1267763. PubMed ID: 38379896
[No Abstract] [Full Text] [Related]
34. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Wang X; Bao Z; Zhang X; Li F; Lai T; Cao C; Chen Z; Li W; Shen H; Ying S
Oncotarget; 2017 Aug; 8(35):59901-59914. PubMed ID: 28938692
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
36. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
38. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
Ni X; Xing Y; Sun X; Suo J
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
[TBL] [Abstract][Full Text] [Related]
40. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
